
like amneal growth stori up pt
report better expect result reflect solid
execut gener specialti brand segment think
may one best posit co gener industri base
sizabl pipelin anda file brand gener sale
mani major gener co includ buy pt
teva teva sell pt experienc greater yoy
declin us gener segment show yoy drop
gross margin show basi point improv
vs new product launch contribut revenu
higher sale product like yuvafem aspirin dipyraidamol
diclofenac gel addit grow specialti brand segment
gener revenu exceed estim
gross margin brand segment remain high
believ sustain co lower ebitda guidanc
 adj ep target
 much declin due on-going epinephrin
suppli shortag due manufactur issu pfizer
rate think eventu rectifi sum believ
manag team led ceo rob stewart execut track
meet possibl even exceed ebitda
estim respect increas pt
share
take action streamlin oper phase
hayward facil expect complet timelin month
nearli one year ahead schedul expect transfer product
manufactur hayward facil co lower-cost facil
us india
worth brand gener product
pipelin capabl spread across variou dosag form
includ oral solid liquid topic inject patch
valuat arriv pt via dcf analysi
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
brand product like rytari treat parkinson diseas zomig nasal spray treat
migrain show solid growth trend yoy
amneal launch gener welchol colesevelam tablet mg grab share month
market
co lower ebitda guidanc adj ep target
 much declin due on-going epinephrin suppli shortag due
manufactur issu pfizer think eventu rectifi
report better expect result higher revenu expect vs estimate
adj earn per share vs estimate
incom statement revenu exclud litig impair incom expens debt averag basic averag dilut revenu litig compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
